Background: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic
steatohepatitis (NASH) are metabolic disorders that affect the liver. A world crisis
is unfolding as the number of people with NAFLD/NASH is substantially increasing.
Chronic liver disease is now estimated to be the leading cause for liver transplant.
Studies have shown that NAFLD/NASH is often more pronounced in certain ethnic
populations, particularly Asian and Hispanic communities. An explanation for this
increased incidence may be associated with intrinsic ethnic factors and/or genetic
polymorphism (variants in a particular DNA sequence). Further, the etiology of
NAFLD/NASH is also linked to obesity, diabetes, and other risk factors which are
highly pronounced in racial communities. Unfortunately, there currently is no
NAFLD/NASH-specific medication on the market to treat these diseases. New drug
development and ongoing research is necessary to treat and cure NAFLD/NASH,
with particular attention given to engage high risk populations. Importantly,
the discovery of new treatments may be beneficial with ongoing support and
collaboration between the research community and ethnic groups.
Conclusion: For NAFLD/NASH clinical studies, participation of Asians and Hispanics is vital and may be important in drug development programs for successful and targeted treatment.
Sharon H Jaycox
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2017 All rights reserved. iMedPub Last revised : January 19, 2017